cgp 42112a has been researched along with Atherogenesis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bosnyak, S; Gaspari, TA; Jones, ES; Kljajic, ST; Vinh, A; Welungoda, I; Widdop, RE | 1 |
| Hongo, S; Kanome, T; Miyazaki, A; Nishio, K; Takahashi, K; Watanabe, T | 1 |
2 other study(ies) available for cgp 42112a and Atherogenesis
| Article | Year |
|---|---|
Direct ATâ‚‚ receptor stimulation is athero-protective and stabilizes plaque in apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cardiotonic Agents; Cohort Studies; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligopeptides; Plaque, Atherosclerotic; Receptor, Angiotensin, Type 2 | 2013 |
Angiotensin II upregulates acyl-CoA:cholesterol acyltransferase-1 via the angiotensin II Type 1 receptor in human monocyte-macrophages.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Endocytosis; Foam Cells; Humans; Imidazoles; Macrophages; Male; Oligopeptides; Radioimmunoassay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Signal Transduction; Sterol O-Acyltransferase; Tetrazoles; Up-Regulation; Vasoconstrictor Agents; Vasodilator Agents | 2008 |